Health
-
STAT+: Medical journal argues a drug maker’s libel suit is really a public relations campaign to chill research
File this under “Not every legal brief is eye-glazing.” Two months ago, Pacira Biosciences (PCRX) took the highly unusual step…
Read More » -
EU loses bid for faster deliveries of AstraZeneca Covid-19 vaccine
The European Union failed in its attempt to force AstraZeneca (AZN) to speed deliveries of its Covid-19 vaccine or face…
Read More » -
A California law that bans drug coupons failed to increase generic use
A California law that banned coupons for brand-name prescription drugs failed to significantly boost greater use of cheaper generics during…
Read More » -
STAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and…
Read More » -
STAT+: Pharmalittle: Biden to spend $3 billion to develop Covid-19 pills; most Americans believe the new Alzheimer’s drug will be effective
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you…
Read More » -
Many Americans concerned about FDA process for Alzheimer’s drug
Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment believe the medication will be…
Read More » -
FDA inaction is holding back 3D bioprinting of transplantable organs
Right now, more than 100,000 Americans are waiting for organ transplants. Due to a lack of available kidneys, livers, hearts,…
Read More » -
Clinicians open their notes to patients in grand experiment in medical care
When Glenda Thomas of Framingham, Mass., checked her doctors’ notes online after a recent infusion, she saw something that stuck…
Read More » -
Athira Pharma CEO placed on leave amid claims of altered images
The chief executive of Athira Pharma, a biotech developing treatments for Alzheimer’s and other neurodegenerative diseases, has been placed on…
Read More » -
Controversial decision won’t stop me from serving on FDA advisory panels
Last week’s controversial decision by the FDA to give aducanumab, Biogen’s Alzheimer’s drug, accelerated approval turned the spotlight on the…
Read More »
